🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

160 results for “Vertex Pharmaceuticals (Ireland) Limited” Clear

  1. Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  2. Biological/Vaccine

    Vertex Pharmaceuticals (Ireland) Limited

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  3. CTX001

    Vertex Pharmaceuticals (Ireland) Limited

    Beta-Thalassemia

    phase 3 mab active

    1 trial

  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Ireland) Limited

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  5. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Ireland) Limited

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  6. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Ireland) Limited

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  7. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex Pharmaceuticals (Ireland) Limited

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  8. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    19 trials

  9. Exa-cel

    Vertex Pharmaceuticals (Ireland) Limited

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  10. IVA

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  11. Ivacaftor

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials

  12. Kalydeco 150 mg film-coated tablets, VX-770 Film-coated tablet, Kalydeco 75 mg film-coated tablets, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, VX-770 Film-coated tablet, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination tablet, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  13. Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kalydeco 59.5 mg granules in sachet, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-121/VX-661/VX-561 granules, VX-445/VX-661/VX-770 fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, VX-121/VX-661/VX-561

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  14. LUM

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  15. Lumacaftor

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  16. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  17. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  18. MP-424

    Vertex Pharmaceuticals (Ireland) Limited

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  19. MP-424

    Vertex Pharmaceuticals (Ireland) Limited

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  20. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Ireland) Limited

    Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  21. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Ireland) Limited

    Infection

    phase 3 small molecule terminated

    1 trial

  22. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Ireland) Limited

    Hepatitis C

    phase 3 mab completed

    1 trial

  23. Placebo

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  24. Povetacicept

    Vertex Pharmaceuticals (Ireland) Limited

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources